Merck's COVID-19 drug to be reviewed by U.S. FDA advisers- Bloomberg News

This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEH9D166_L.jpg

The advisory committee will weigh in on molnupiravir’s safety concerns, which have been raised by some experts, before the FDA makes a decision on authorization of the drug, the report https:// said.

Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.

Pfizer Inc (NYSE:PFE) and Swiss drugmaker Roche Holding AG (OTC:RHHVF) are also racing to develop an easy-to-administer antiviral pill for COVID-19.

Merck is developing molnupiravir in partnership with U.S.-based Ridgeback Biotherapeutics.

In early October, data showed Merck’s drug could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, pummelling shares of coronavirus vaccine makers.

The FDA and Merck did not immediately respond to Reuters’ requests for comment.

Add Comment